

**Compelling Vision** 

**Proven Methods** 


**Barriers to Scale** 

#### **Agenda**

- Brief Background
- Compelling Vision:
  - A Story: What Get's in Your Way?
  - What is a Learning Health Network? How does it work?
- Proven Methods
  - Success and Impact of Healthier Together Learning Networks
- Barriers to Scale
  - Challenges to function, progress, and scale
  - Opportunities to realize vision

# Background

#### People with ESKD die young



United States Renal Data System. 2020 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2020.


# Healthcare delivery system inadequate to address complex challenges

- Available therapies improve health, but they are not used reliably
  - Providers prescribe appropriate therapy < 60% of time
  - Patients experience barriers to taking their medication
    - poor adherence costs \$300 billion annually in the US
  - 40% of kidney transplant failure attributed to poor adherence
    - Return to dialysis costs the patient 35 years of life for care that costs 2-3 times as much
- Rare conditions require multi-center collaboration to generate knowledge and know how
  - What to do…
  - How to get it done in actual practice
- Translation of evidence into practice takes 17 years.


# **Compelling Vision**

A Patient Story

Patient Born with Renal Dysplasia: KB



#### **Adherence Center: % of Doses Taken**





# Co-production

patients, clinicians, researchers, administrators working together

#### Patients, Clinicians, Researchers, Administrators



#### **Improving Renal Outcomes Collaborative**







**Vision:** Partner with patients to improve health, longevity, and quality of life by engaging all stakeholders

#### **IROC INTERVENTION PACKAGES**

PARTNERING TO ACHIEVE HEALTH, LONGEVITY, AND QUALITY OF LIFE



#### **IROC INTERVENTION PACKAGES**

PARTNERING TO ACHIEVE HEALTH, LONGEVITY, AND QUALITY OF LIFE

#### INTERVENTIONS BY PACKAGE


REDUCE ACUTE ALLOGRAFT REJECTION	Kidney.Me	Pre-Visit Planning
		Customized Type & Group Visits
		Transition Support
		Caregiver's Virtual Roadmap
		Individualizable Adherence Evaluation & Treatment Toolfit
	Improving Adherence	Network-activated Peer Mentoring
		Total Adherence App
		Patient/Parent Exchange Platform
		Transplant Pharmacist on Call
		Individualizable Adherence Evaluation & Treatment Toolkit
		Pre-Visit Planning with Adherence Data
	Rejection Prevention	Central IRBs
	Research	Explore Pediatrics vs Adult
		Enhanced Solution Shop
		IROC Exchange
		Mentorship for Research


## **Model for Improvement**

Designing, testing, refining, implementing a Medication Adherence Promotion System at Cincinnati Children's Hospital

#### **Quality Improvement Project Aim**

- Decrease late acute allograft rejection by:
  - Developing and implementing systems to identify and mitigate patient-identified barriers to adherence in clinic with existing staff






Medication
Adherence
Promotion
System: (MAPS)

#### Model for Improvement

What are we trying to accomplish?

How will we know that a change is an improvement?

What change can we make that will result in improvement?




#### **Barriers assessment**

Developed and refined through iterative testing with *patients, parents*, and providers.

14 item checklist (yes/no)


Reliably implemented through iterative testing through PDSA cycles starting with 1 patient, then 5, then 25, then all.




# Research with Clinical Data

#### **Results: Patient-Identified Barriers (n=98)**

98 patients represented M(SD) age = 13.9 (6.4) years



- Endorsed Barrier
- No Barrier



Patient did not identify a barrier -- Patient identified a barrier
 Varnell et. al., Peds Neph, 2020


#### **Multivariable Analysis**

Table 4. Multivariable Survival Analysis: Incidence Rate Ratio of Late Acute Rejection

Risk Factor	Incidence Rate Ratio (95% CI)	p-value
Pre-MAPS (vs. Post-MAPS)	0.50 (0.27-0.91)	0.02
DSA History	2.27 (1.12-4.57)	0.02
Repeat Kidney Transplant	1.65 (0.53-5.16)	0.39
<b>Deceased Donor</b>	0.58 (0.23-1.45)	0.24
<b>Minority Status</b>	0.56 (0.24-1.34)	0.19
Prior Rejection	1.37 (0.65-2.91)	0.41
HLA Mismatch	1.41 (0.63-3.20)	0.41
Time Since Transplant	0.87 (0.77-0.97)	0.02

Abbreviations: CI—Confidence Interval; CNI—Calcineurin Inhibitor; DSA-Donor Specific Antibody; HLA—Human Leucocyte Antigen; MAPS—Medication Adherence Promotion System

# MAPS is cost Saving and Cost-Effective over a wide ranges or Efficacy "Cost saving" so long as it





MAPS Acute Rejection Rate (per year)

# Network Based Coproduction and Spread

Improving Renal Outcomes Collaborative

# Educational Materials Coproduced with Patients, Families, and Clinicians








































































(PH

The Children's Hospital of Philadelphia®

PHOENIX CHILDREN'S Hospital





### **Innovation and Scale**

Developing a Digitally Enabled Adherence Platform for spread and scale to other patients with chronic illness


#### **IROC INTERVENTION PACKAGES**

PARTNERING TO ACHIEVE HEALTH, LONGEVITY, AND QUALITY OF LIFE

#### INTERVENTIONS BY PACKAGE

REDUCE ACUTE ALLOGRAFT	Kidney.Me	Pre-Visit Planning
REJECTION	,	Customized Type & Group Visits
		Transition Support
		Caregiver's Virtual Roadmap
		Individualizable Adherence Evaluation & Treatment Too.
	Improving Adherence	Network-activated Peer Mentoring
		Total Adherence App
		Patient/Parent Exchange Platform
		Transplant Pharmacist on Call
		Individualizable Adherence Evaluation & Treatment Toolkit
		Pre-Visit Planning with Adherence Data
	Rejection Prevention	Central IRBs
	Research	Explore Pediatrics vs Adult
		Enhanced Solution Shop
		IROC Exchange
		Mentorship for Research

#### **Digitally Enabled Adherence Platform**




# Learning Health System VS. Traditional Approach

#### **MAPS**




■BL Yr 1 ■BL Yr 2 ■MAPS Yr 1 ■MAPS Yr 2

#### TakeIT! Multi-center RCT



#### LHS Vs. Traditional Approach



### How?



### **Proven Methodology**

R&D: First 15 years—Developing and Proving the Methods

## **Learning Health Network**



Community
(ALL stakeholders
"Actors" engaged social
network)



Technology/Registry (infrastructure for data/knowledge sharing, "Commons")



Methodology (Processes and Policies)

## **Our Community of Networks**





























### Results







Centerline (1.073)

- Goal (0.601)

----- Control Limits

→ Monthly Network Rate





# **Barriers to Scale**

Designing for Scale: Looking to the Future



- How to build and govern a thriving, collaborative community of networks
- 2. A business and financial strategy for growing and sustaining the community and individual networks.
- 3. How to use technology, data, and analytics to facilitate innovation, sharing, improvement, and research
- 4. How to grow and enhance co-production
- 5. How to build scalable systems improvement capability
- 6. How to accelerate research and learning

### "Luck is the residue of design" - Branch Rickey

### Building and governing a community of networks

#### **Existing Networks**

- 1. Hospital Safety (Solutions for Patient Safety)
- 2. IBD (ImproveCareNow)
- 3. Kidney Transplant (Improving Renal Outcomes Collaborative)
- 4. Ohio Perinatal Quality Collaborative
- 5. Asthma Learning Health System
- 6. Hypo-plastic left heart syndrome (National Pediatric Cardiology Quality Improvement Collaborative)
- 7. Fontan Outcomes Network
- 8. Community Health (All Children Thrive Cincinnati)
- 9. Congestive heart failure (ACTION)
- 10. Hospital cardiac care (PAC 3 and 4)
- 11. Cystic Fibrosis Learning Network
- 12. Autism Learning Health Network
- 13. Epilepsy Learning Health Network
- 14. Pancreatic Cancer (Canopy Cancer Collective)
- 15. Pediatric rheumatology collaborative improvement network (PR-COIN)

#### **Prospective Networks**

Adult kidney transplant
Posterior urethral valves (pediatric)\*
Adult safety

#### Cancer

- Bone marrow transplant (life span)\*
- Oncology survivorship (life span)\*
- BRCA Breast Cancer
- Multiple myeloma
- Colon cancer

#### Mental/behavioral health

- Anxiety disorders
- ADHD
- Depression

### Cross-cutting networks

- Equity
- Adherence
- Emotional health and resilience

Public Health Preparedness
Trach dependent children



16. Sickle Cell Network

17. Bipolar Disorder (life span)

### Collaboration, Business and Financial Barriers


- One-at-a-time model does not scale
  - "Does there need to be a new network for every condition? How could hospitals join more networks?" Tina Cheng, MD, MPH Dept. Chair, CCHMC
- Limited efficiency
  - Inter-related conditions
  - Cross-cutting needs (e.g., mental health, adherence)
  - How to prioritize new networks for biggest impact
- Network infrastructure not yet robust or shared
- No stable financing for primary network benefit of better health outcomes or "byproducts" (e.g., research)



- How to build and govern a thriving, collaborative community of networks
- 2. A business and financial strategy for growing and sustaining the community and individual networks.
- 3. How to use technology, data, and analytics to facilitate innovation, sharing, improvement, and research
- 4. How to grow and enhance co-production
- 5. How to build scalable systems improvement capability
- 6. How to accelerate research and learning

### "Luck is the residue of design" - Branch Rickey

## % Patients with Visit Entered in Last 4 Months By Center



## **Technology and Analytic Barriers**

- Excessive burden of data capture
  - Including local IT effort to implement tools for data capture (e.g., FHIR)
- Cost of building and maintaining registries
- Not taking full advantage of existing and new data sources
  - More advanced analytics as part of care planning
  - Tools to support knowledge sharing (e.g., recommender engines for QI)
  - New data sources (PROs, sensors, data linkages public health + clinical + prescription)




- How to build and govern a thriving, collaborative community of networks
- 2. A business and financial strategy for growing and sustaining the community and individual networks.
- 3. How to use technology, data, and analytics to facilitate innovation, sharing, improvement, and research
- 4. How to grow and enhance co-production
- 5. How to build scalable systems improvement capability
- 6. How to accelerate research and learning

### "Luck is the residue of design" - Branch Rickey

### **Growing and enhancing co-production**

### Research



### Care





#### **Innovation**



Despite these advances, still too hard for <u>all</u> patients to participate





- How to build and govern a thriving, collaborative community of networks
- 2. A business and financial strategy for growing and sustaining the community and individual networks.
- 3. How to use technology, data, and analytics to facilitate innovation, sharing, improvement, and research
- 4. How to grow and enhance co-production
- 5. How to build scalable systems improvement capability
- 6. How to accelerate research and learning

### "Luck is the residue of design" - Branch Rickey


## **Scalable Quality Improvement Capacity**

Complex Environments with Competing Priorities






## **IROC Pathway to Mastery**



Kidney Transplant Ideal Outcome



### **Constraints to Scaling Improvement Capability**

- Workforce: Limited improvement capability in many care centers
  - Staff turnover
  - Lack of staff
- QI competencies and execution: Discipline and process to apply methods at a high level
- Knowledge sharing: Re-inventing improvement projects
- Organizational incentives: Participation in QI is considered "Extra" in current payment environment



- How to build and govern a thriving, collaborative community of networks
- 2. A business and financial strategy for growing and sustaining the community and individual networks.
- 3. How to use technology, data, and analytics to facilitate innovation, sharing, improvement, and research
- 4. How to grow and enhance co-production
- 5. How to build scalable systems improvement capability
- 6. How to accelerate research and learning


### "Luck is the residue of design" - Branch Rickey

### **Barriers to Accelerating Research and Learning**

- Variation in research infrastructure across networks and care centers
- Administrative friction for data sharing (time to contract, policies and processes to steward data)
- Researchers usually determine priorities
- Incentives for promotion do not favor collaboration
- Constraints on full patient participation
  - Training
  - Money to fund patient research priorities
  - Patients forced to volunteer to participate

# **The Opportunity**

## **Learning Network Eco-System**



#### **Domains:**

- 1. Professional staffing organization
- 2. Training and Professional Development
- 3. Technology Platform
- 4. Learning system
- 5. Governance, Legal, Regulatory
- 6. Communication, marketing, branding, advocacy
- 7. Business Development, Fund Raising, Grant writing
- 8. Application and Services marketplace



Questions/Discussion

